Home > Boards > Free Zone > User's Groups > AMA''s Stock Market Insights

PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AMA Member Profile
Followed By 700
Posts 64,217
Boards Moderated 1
Alias Born 12/05/06
160x600 placeholder
ECB Keeps Monetary Stimulus on Track Amid Recession Concerns -- 2nd Update
FRANKFURT -- The European Central Bank will keep its aggressive monetary stimulus in place and lag the Federal Reserve in phasing it out, ECB President Christine Lagarde said, as the eurozone wrestles with a fresh wave of Covid-19 infections that likely tipped the bloc back into recession early this year.
U.S. Treasury Yields Rise After Jobs Data
Top Company News of the Day
Tesla Crashes Raise Safety Questions in Congress About Driver-Assistance Systems -- Update
Northrop Grumman to Proceed With SATCOM Prototype for Space Force
Vivendi 1Q Revenue Increased, Supported by Universal Music -- Update
NYC Sues Exxon, Shell, BP and Trade Group for Advertising-Related Claims
Vivendi: Strong Increase in Revenues for the First Quarter Of 2021 (+5.0% at Constant Currency and Perimeter)
Hewlett Packard Enterprise, Facebook and Microsoft Team Up on Low-Carbon Pledge
Vinci 1Q Revenue Was Slightly Higher; Backs 2021 Outlook
Vivendi 1Q Revenue Rose Supported by Universal Music
Growth of Manufacturing Activity in Central U.S. Soars in April to Record-High -- Kansas City Fed
Blackstone Notches Record $1.75 Billion Profit as Growth Strategy Pays Off
Dow Down Over 5%, on Track for Largest Percent Decrease Since June 2020 -- Data Talk
AT&T's Revenue Rises as Wireless Unit, HBO Add Customers--2nd Update
Lowe's Buys Stainmaster Flooring Brand From Koch Industries
U.S. Unemployment Claims Hit New Covid-19 Pandemic Low -- 3rd Update
AT&T Up Over 5%, Most Active Stock in the S&P 500 So Far Today -- Data Talk
Exxon Expands Renewable Fuels Agreement with Global Clean Energy Holdings
U.S. March Existing-Home Sales Drop on Tight Supply -- Update
AMA   Monday, 01/04/21 08:30:17 PM
Re: None
Post # of 30835 
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire/ – INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), an emerging biotech company with next-generation technology in vaccines, both preventive and therapeutic, today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

Under the collaboration and license agreement, Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will license its plasmid manufacturing process for use with INO-4800 and other INOVIO pipeline product candidates to INOVIO with the right to sublicense to INOVIO’s manufacturing partners. Additionally, Advaccine will provide its clinical data to INOVIO in support of INOVIO’s global INO-4800 regulatory filings and INOVIO will provide its INO-4800 clinical data for Advaccine to incorporate into its marketing applications in Greater China. Advaccine will make to INOVIO an upfront payment of $3.0 million as well as pay an aggregate of $108.0 million upon the achievement of specified development and sales-based milestones for INO-4800 in Greater China. INOVIO will be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China.

Dr. J. Joseph Kim, President and Chief Executive Officer of INOVIO, said, “INOVIO’s partnership with Advaccine enables us to leverage their deep expertise, capabilities and network across the region – making it possible to rapidly produce and if and when approved, distribute our vaccine candidate to more people across Greater China. This agreement also provides INOVIO with an Asian manufacturing partner with a near-term focus on INO-4800 and a long-term manufacturing resource potentially for other INOVIO products. We are grateful for Advaccine joining our global manufacturing coalition as a dedicated resource for Greater China and look forward to our continued partnership in the fight against COVID-19.”

Dr. Bin Wang, Founder and Chairman of Advaccine, said, “We are proud to build upon our current partnership with INOVIO and join their global manufacturing consortium. Advaccine will leverage its innovative large-scale DNA plasmid manufacturing process developed over years — our GMP manufacturing facility in Suzhou has the capacity to produce over one hundred million doses of DNA vaccine per year. Given the strong safety profile and robust immune responses observed in the U.S. and China clinical trials of INO-4800, we are confident in the vaccine candidate and are fully committed to the manufacturing of INO-4800 for Greater China. INO-4800 is projected to be stable at room temperature for over a year, at 37oC for more than a month, and with a five-year projected shelf life at normal refrigeration temperature. INO-4800 does not need to be frozen during transport or storage – a critical element when considering the feasibility of distribution in Greater China and globally.”

INOVIO and Advaccine have been working together to advance the clinical development of INO-4800 in China, having all 640 subjects dosed for the first vaccination in Phase 2 clinical trial in China. The Phase 2 clinical trial of INO-4800 in China has enrolled both adults who are 18-59 years old and older adults (60 years and older) with the primary endpoints of evaluating safety and immunogenicity within the Chinese population. The dosing regimen involves two vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels, similar to the independently run Phase 2 segment of INOVIO’s Phase 2/3 clinical trial for INO-4800 in the U.S, called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy).

INOVIO also recently announced it has started dosing of subjects in the Phase 2 segment of INNOVATE. For more information about the INNOVATE clinical trial, see www.clinicaltrials.gov, identifier NCT04642638.

About the INO-4800 “INNOVATE” Phase 2/3 Clinical Trial

The lead Principal Investigator for INNOVATE is Dr. Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment of the clinical trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization (in a planned total of 400 subjects) to receive either INO-4800 or placebo, to confirm the more appropriate dosing level for each of three age groups (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The company strives to ensure diversity in enrollment, targeting specific populations that are working or residing in environments with high risk of exposure to SARS-CoV-2, for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings.

The INNOVATE trial is funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA). In the planned Phase 3 segment of the trial, INOVIO intends to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed dosing level(s) for each age group based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences